25 Oct 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Sigma-Aldrich reported that its sales increased two percent to $639 million. Sales of research and fine chemicals grew by one percent and five percent, respectively. Acquisitions contributed six percent to sales growth. Changes in foreign currency exchange rates reduced the reportable sales by six percent.
The firm reported Q3 2012 diluted EPS of $0.92 as compared to $0.95 in Q3 2011. Excluding restructuring costs, Q3 2012 adjusted diluted EPS was $0.94 as compared to $0.96 in Q3 2011.
Overall organic sales growth for the full year 2012 is expected to be about three percent, within our prior guidance of low-to-mid single digits. Research sales are expected to grow organically in the low single digits in Q4 2012. SAFC sales are expected to grow in the mid-to-high single digits in Q4 2012. Acquisitions are expected to increase 2012 sales growth by approximately six percent. At current rates, foreign currency exchange rate changes are expected to reduce otherwise reportable sales for the full year 2012 by approximately three.
Guidance for adjusted diluted 2012 EPS (excluding restructuring charges, one-time acquisition-related transaction costs, and any other special charges) remains unchanged at $3.80-to-$3.90. Net cash provided by operating activities and free cash flow is expected to exceed $525 million and $400 million, respectively, for 2012, and is the same as prior guidance.
Commenting on third quarter 2012 performance, president and CEO, Mr Rakesh Sachdev said that, "We were able to deliver $0.94 adjusted EPS, which includes an $0.11 EPS headwind for unfavorable year-over-year changes in foreign currency exchange rates, while generating two percent overall organic sales growth."